Condition: Shock, Cardiogenic · Sponsor: Ottawa Heart Institute Research Corporation
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
This description comes directly from the study's public registry record.
Rebecca Mathew, MD · 613-696-7406 · rmathew@ottawaheart.ca
Baylie Morgan, RN · 613-696-7000 · bmorgan@ottawaheart.ca
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| Hamilton Health Sciences | Hamilton, Ontario, Canada | Recruiting |
| University of Ottawa Heart Institute | Ottawa, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05267886